In both studies, the primary efficacy endpoint was progression-free survival.

在两项研究中，主要功效评估指标是无进展生存期。

youdao

All 185 patients were included in the analysis of progression-free and overall survival.

全部185名患者参与了无疾病进展及总体生存的分析。

youdao

The median progression-free survival period with the drug combination was 11.8 months, twice as long as the 5.9 months achieved with paclitaxel alone.

药物联用的中值无进展存活期为11.8个月，是用单独紫杉醇获得的5.9个月的两倍。

youdao

The median progression-free survival for patients receiving T-DM1 was 9.6 months, compared to 6.4 months in the group receiving Xeloda and Tykerb, a difference considered statistically significant.

WSJ: Roche Breast-Cancer Treatment Advances

In a tougher measure of efficacy that takes into account how long patients lived, called progression-free survival, Thalomid more than doubled the length of time patients lived, to 57 weeks.

FORBES: Thalomid Fuels Celgene's Rise

While the drug combo did meet the first goal of increasing progression-free survival, it failed to prolong overall survival beyond what is normal for patients on chemotherapy without Erbitux.

FORBES: Market Scan